Syndrome News and Research

RSS

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Discovery Laboratories, Inc., a biotechnology company developing its novel synthetic surfactant and aerosol technologies for respiratory diseases, today provides an update on Surfaxin® and key pipeline and business initiatives and reports financial results for the first quarter ended March 31, 2010.

28 Apr 2010

Lexicon Pharmaceuticals to present Phase 2 study results of LX1031 for non-constipating IBS at DDW 2010

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that the company will be giving poster and oral presentations on results from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) at Digestive Disease Week (DDW) 2010 in New Orleans, Louisiana.

28 Apr 2010

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has published results from its Phase II GEMINI study in the Proceedings of the National Academy of Sciences (PNAS). These data, previously presented at the International Symposium on Respiratory Viral Infections in Singapore in 2008, showed human proof of concept with an RNAi therapeutic in a randomized, double blind, placebo-controlled study.

27 Apr 2010

IBS patients treated with cognitive behavior therapy have positive response: Study

A significant proportion of irritable bowel syndrome patients treated with cognitive behavior therapy have a positive response within four weeks of treatment, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

27 Apr 2010

Grape-enriched diet prevents risk factors for metabolic syndrome: Researchers

Scientists at the University of Michigan Health System are teasing out clues to the effect of grapes in reducing risk factors related to cardiovascular disease and metabolic syndrome. The effect is thought to be due to phytochemicals -- naturally occurring antioxidants - that grapes contain.

26 Apr 2010

Mothers with preeclampsia at reduced risk of developing breast cancer

Preeclampsia is a high blood pressure syndrome in pregnant mothers that is caused when the blood supply in the placenta of the developing baby is restricted. The blood-deprived placenta releases factors that cause the raise in blood pressure in the mother. Doctors have to monitor these women closely and they may be forced to deliver the baby early to protect the mother and the baby. Most women's blood pressure returns to normal levels after they deliver the placenta.

26 Apr 2010

Serum cortisol levels linked with increased mortality in patients with ACS: Research

Growing evidence suggests that serum cortisol levels are associated with increased cardiovascular mortality in patients with chronic heart failure, research presented at this week's European Congress of Endocrinology shows.

26 Apr 2010

Urigen Pharmaceuticals requests FDA meeting for advancing URG101 clinical program

Urigen Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that it has filed a request for an FDA meeting to advance the URG101 clinical program and mutually agreed with Oceana Therapeutics, Inc. to terminate their Consulting Agreement effective immediately.

24 Apr 2010

Researchers take major step to predict adverse drug reactions using genetic information

In a new study, researchers at Mount Sinai School of Medicine have taken a major step toward the ability to predict adverse drug reactions, using genetic, cellular, and clinical information to learn why some medicines cause heart arrhythmias in patients. Published in the April 20 issue of the journal Science Signaling, the new framework described in the study could potentially be applied to the study of medications that treat other diseases and disorders such as epilepsy and autism.

23 Apr 2010

Study describes relationship between gene expression and intelligence in WS patients

Although genetics is the most significant known determinant of human intelligence, how specific genes affect intelligence remains largely unknown. A multi-institution team led by a University of Utah USTAR researcher has found that the brain gene STX1A plays a significant role in the level of intelligence displayed by patients with Williams Syndrome.

23 Apr 2010

Researchers to measure children with Down syndrome to develop new growth charts

Parents and doctors have known for a long time that children with Down syndrome tend to grow more slowly and are considerably shorter than most other children. But pediatricians needing to record growth milestones at regular office visits have an outdated set of growth charts based on data collected more than 25 years ago.

23 Apr 2010

Alexion Pharmaceuticals reports total revenues of $117.6M from net product sales of Soliris

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter ended March 31, 2010.

22 Apr 2010

DDW2010 Investor Event to provide update on TARGET 1 and TARGET 2 Phase 3 trials

Salix Pharmaceuticals, Ltd. today announced that the Company will host a DDW2010 Investor Event on Monday, May 3 2010 from 9:00 p.m. to 10:00 p.m. Central Time (10:00 p.m. to 11:00 p.m. ET).

22 Apr 2010

Investment report on Array BioPharma

MicroStockProfit.com announces an investment report featuring Array BioPharma Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

21 Apr 2010

Contrary to previous studies, people with Moebius syndrome lead successful lives

A smile means happiness, a frown sadness, a raised brow surprise. Even when languages and cultures differ, people have this universal form of communication. But Moebius syndrome, a rare congenital condition causing facial paralysis, can rob people of this basic connection, affecting social interaction.

21 Apr 2010

Children with developmental regression at increased risk for more severe autism: Study

Kennedy Krieger Institute announced today new study results showing that when and how autism symptoms appear in the first three years of life has vital implications to a child's developmental, diagnostic, and educational outcomes.

21 Apr 2010

Systems biologists integrate new genetic framework to help predict adverse drug reactions

In a major step toward predicting adverse drug reactions, systems biologists at Mount Sinai School of Medicine in New York City have integrated genetic, cellular and clinical information to find out why certain medicines can trigger fatal heart arrhythmias.

21 Apr 2010

CSTE receives $1M gift from NFL to research long-term effects of repetitive brain trauma in football players

The National Football League (NFL) will give a $1 million unrestricted gift to the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine to support the Center's research.

21 Apr 2010

Patients dismissed from hospital with noncardiac chest pain continue to experience cardiac events: Study

The growing number of Americans with cardiovascular disease has caused a heightened sensitivity in the evaluation of chest pain. In a study published in the April issue of Mayo Clinic Proceedings researchers reported that patients dismissed from the hospital with noncardiac chest pain continue to experience cardiac events, which may highlight a need for more aggressive cardiovascular risk factor management in this population.

21 Apr 2010

Alexion Pharmaceuticals completes enrollment in Soliris clinical studies for aHUS

Alexion Pharmaceuticals, Inc. today announced that it has completed enrolling patients in all four previously announced prospective, open-label clinical studies investigating Soliris® (eculizumab) as a potential treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) being conducted in North America and multiple European countries.

21 Apr 2010

Syndrome News and Research

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Lexicon Pharmaceuticals to present Phase 2 study results of LX1031 for non-constipating IBS at DDW 2010

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

IBS patients treated with cognitive behavior therapy have positive response: Study

Grape-enriched diet prevents risk factors for metabolic syndrome: Researchers

Mothers with preeclampsia at reduced risk of developing breast cancer

Serum cortisol levels linked with increased mortality in patients with ACS: Research

Urigen Pharmaceuticals requests FDA meeting for advancing URG101 clinical program

Researchers take major step to predict adverse drug reactions using genetic information

Study describes relationship between gene expression and intelligence in WS patients

Researchers to measure children with Down syndrome to develop new growth charts

Alexion Pharmaceuticals reports total revenues of $117.6M from net product sales of Soliris

DDW2010 Investor Event to provide update on TARGET 1 and TARGET 2 Phase 3 trials

Investment report on Array BioPharma

Contrary to previous studies, people with Moebius syndrome lead successful lives

Children with developmental regression at increased risk for more severe autism: Study

Systems biologists integrate new genetic framework to help predict adverse drug reactions

CSTE receives $1M gift from NFL to research long-term effects of repetitive brain trauma in football players

Patients dismissed from hospital with noncardiac chest pain continue to experience cardiac events: Study

Alexion Pharmaceuticals completes enrollment in Soliris clinical studies for aHUS

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News